GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » EPS without NRI

Rocket Pharmaceuticals (Rocket Pharmaceuticals) EPS without NRI : $-2.87 (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals EPS without NRI?

Rocket Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.66. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.87.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -5.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -13.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Rocket Pharmaceuticals's EPS without NRI or its related term are showing as below:

RCKT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.3   Med: -12.2   Max: 37.3
Current: -5

During the past 12 years, Rocket Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 37.30% per year. The lowest was -27.30% per year. And the median was -12.20% per year.

RCKT's 3-Year EPS without NRI Growth Rate is ranked worse than
62.7% of 1303 companies
in the Biotechnology industry
Industry Median: 5.6 vs RCKT: -5.00

Rocket Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.66. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.87.

Rocket Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-0.66. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.87.


Rocket Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Rocket Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals EPS without NRI Chart

Rocket Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.58 -2.52 -2.67 -3.26 -2.92

Rocket Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -0.82 -0.75 -0.64 -0.66

Competitive Comparison of Rocket Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Rocket Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's PE Ratio without NRI falls into.



Rocket Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rocket Pharmaceuticals  (NAS:RCKT) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Rocket Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Rocket Pharmaceuticals (Rocket Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Executives
John Militello officer: See Remarks C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Gotham Makker director 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Gaurav Shah director, officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Kinnari Patel officer: Chief Operating Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Mark Andrew White officer: Chief Medical Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
Jonathan David Schwartz officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Martin Wilson officer: General Counsel C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Carlos Garcia-parada officer: Chief Financial Officer C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork director C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam officer: SVP - Finance & PFO 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
David P Southwell director, officer: See Remarks C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Naveen Yalamanchi director 412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Headlines